Janssen Pharmaceuticals Inc. is responding to Pfizer Inc.’s announcement that it will launch Inflectra next month with a promise to turn to contracting and pricing to maintain market share for Remicade.
Pfizer announced Oct. 17 that it will begin shipping its biosimilar of Janssen’s tumor necrosis factor inhibitor in “late November.” Inflectra (infliximab-dyyb) is partnered with Celltrion Inc.
Inflectra’s Indications
- adult patients and pediatric patients (ages six years and older) with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy;
- adult...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
